Copyright
©The Author(s) 2022.
World J Gastroenterol. Aug 28, 2022; 28(32): 4620-4634
Published online Aug 28, 2022. doi: 10.3748/wjg.v28.i32.4620
Published online Aug 28, 2022. doi: 10.3748/wjg.v28.i32.4620
Table 1 Treatment conditions for 28 d
| No. | Group | The route of treatment and dose |
| 1 | Group I (untreated group- distilled water) | Oral (1 mg/kg per day) |
| 2 | Group II (chemodrug-gemcitabine) | Intraperitoneal (10 mg/kg per 3 d) |
| 3 | Group III (low dose of O.s) | Oral (200 mg/kg per day) |
| 4 | Group IV (low dose of O.s -gemcitabine combination) | Oral (200 mg/kg per day) + Intraperitoneal (10 mg/kg per 3 d) |
| 5 | Group V (high dose of O.s) | Oral (400 mg/kg per day) |
| 6 | Group VI (high dose of O.s-gemcitabine combination) | Oral (400 mg/kg per day) + Intraperitoneal (10 mg/kg per 3 d) |
- Citation: Yehya AHS, Subramaniam AV, Asif M, Kaur G, Abdul Majid AMS, Oon CE. Anti-tumour activity and toxicological studies of combination treatment of Orthosiphon stamineus and gemcitabine on pancreatic xenograft model. World J Gastroenterol 2022; 28(32): 4620-4634
- URL: https://www.wjgnet.com/1007-9327/full/v28/i32/4620.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i32.4620